On April 16, 2019 the National Institute for Health and Care Excellence (NICE) releases its final guidance recommending inotersen (Tegsedi) be placed on England’s National Health Service for the treatment of nerve damage from hereditary transthyretin-mediated amyloidosis (hATTR). Read more here.
1 (905) 580-2802
info@madhattr.ca
